| Index | — | P/E | — | EPS (ttm) | -1.19 | Insider Own | 9.79% | Shs Outstand | 95.65M | Perf Week | -3.97% |
| Market Cap | 559.55M | Forward P/E | — | EPS next Y | -0.59 | Insider Trans | -0.08% | Shs Float | 88.60M | Perf Month | 31.88% |
| Enterprise Value | 655.55M | PEG | — | EPS next Q | -0.17 | Short Float | 10.46% | Perf Quarter | 91.75% | ||
| Income | -112.00M | P/S | 0.69 | EPS this Y | — | Short Ratio | 4.42 | Perf Half Y | 20.08% | ||
| Sales | 807.00M | P/B | 1.84 | EPS next Y | — | ROA | -17.62% | Short Interest | 9.27M | Perf YTD | -1.79% |
| Book/sh | 3.18 | P/C | 4.87 | EPS next 5Y | — | ROE | -32.59% | 52W High | 8.38 -27.92% | Perf Year | -24.88% |
| Cash/sh | 1.20 | P/FCF | — | EPS past 3/5Y | — | ROIC | -19.13% | 52W Low | 2.74 120.44% | Perf 3Y | -56.58% |
| Dividend Est. | — | EV/EBITDA | — | Sales past 3/5Y | 6.76% 8.17% | Gross Margin | 68.83% | Volatility | 6.25% 6.86% | Perf 5Y | -80.29% |
| Dividend TTM | — | EV/Sales | 0.81 | EPS Y/Y TTM | — | Oper. Margin | -12.22% | ATR (14) | 0.38 | Perf 10Y | -69.34% |
| Dividend Ex-Date | Jul 01, 2009 | Quick Ratio | 1.98 | Sales Y/Y TTM | -3.12% | Profit Margin | -13.96% | RSI (14) | 63.86 | Recom | 2.97 |
| Dividend Gr. 3/5Y | — | Current Ratio | 2.21 | EPS Q/Q | -600.00% | SMA20 | 15.82% | Beta | 1.57 | Target Price | 4.82 |
| Payout | 0.00% | Debt/Eq | 0.69 | Sales Q/Q | -10.33% | SMA50 | 39.62% | Rel Volume | 0.96 | Prev Close | 5.85 |
| Employees | 2,700 | LT Debt/Eq | 0.67 | Earnings | Nov 04 | SMA200 | 31.09% | Avg Volume | 2.28M | Price | 6.04 |
| IPO Date | Oct 06, 1995 | Option/Short | Yes / Yes | EPS/Sales Surpr. | -422.51% -7.44% | Net Debt/EBITDA | — | Volume | 2,188,691 | Change | 3.25% |
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Oct-20-26 | Reiterated | Wells Fargo | Equal Weight | $3.00 → $4.50 |
| Oct-20-26 | Reiterated | Piper Sandler | Underweight | $2.00 → $5.00 |
| Oct-02-26 | Reiterated | Craig-Hallum | Buy | $18 → $8.00 |
| Sep-09-26 | Reiterated | UBS | Neutral | $6.00 → $3.60 |
| Sep-01-26 | Downgrade | Piper Sandler | Overweight → Underweight | $13 → $2.00 |
| Aug-18-26 | Reiterated | Stephens & Co. | Equal Weight | $22 → $3.00 |
| Aug-03-26 | Reiterated | Wells Fargo | Equal Weight | $6.00 → $3.00 |
| Feb-24-26 | Reiterated | UBS | Neutral | $8.00 → $6.00 |
| Nov-04-25 | Reiterated | UBS | Neutral | $7.00 → $8.00 |
| May-21-25 | Downgrade | Scotiabank | Sector Outperform → Sector Perform |
Myriad Genetics, Inc., a molecular diagnostics and precision medicine company, develops molecular tests. The company offers molecular diagnostic tests for oncology, women’s health, and pharmacogenomics. It also provides MyRisk Hereditary Cancer test, a DNA sequencing test for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic test, a DNA sequencing test for metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer. In addition, the company offers Prolaris Prostate Cancer Prognostic test, an RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic test, an RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor Molecular Profile test, a genomic profiling test; Prequel Prenatal Screen, a non-invasive prenatal screening test conducted using maternal blood to screen for severe chromosomal disorders in a fetus; Foresight Carrier Screen, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; SneakPeek Early Gender DNA test, a non-invasive blood test that predicts the gender of a fetus; FirstGene; and GeneSight Psychotropic Mental Health Medication test, a DNA genotyping test to aid psychotropic drug selection for depression, anxiety, attention-deficit/hyperactivity disorder, and other mental health conditions. It has a license collaboration with Illumina, Inc.; University of Texas M.D. Anderson Cancer Center; Mayo Foundation for Medical Education and Research; Children’s Medical Center in Boston; Institut Curie and INSERM; and Eurobio Scientific SA. The company was founded in 1991 and is headquartered in Salt Lake City, Utah.
Per-holder 13F data hasn't been ingested for this ticker yet.
| Line Item (USD, M) | TTM — | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 6/30/2020 | FY 2018 6/30/2019 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 807 | 825 | 838 | 753 | — | — | — | — | — | |
| Cost of Goods Sold Incl. D&A | 252 | 248 | 252 | 236 | — | — | — | — | — | |
| Gross Profit | 556 | 577 | 585 | 517 | — | — | — | — | — | |
| Selling, General and Administrative Excl. Other | 540 | 538 | 560 | 573 | — | — | — | — | — | |
| Research and Development | 106 | 107 | 113 | 89 | — | — | — | — | — | |
| Other Operating Expense | 8 | -1 | 0 | 0 | — | — | — | — | — | |
| Operating Income | -99 | -68 | -88 | -145 | — | — | — | — | — | |
| Interest Expense | 16 | 11 | 3 | 3 | — | — | — | — | — | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | 3 | -317 | -33 | -115 | — | — | — | — | — | |
| Net Income Before Taxes | -112 | -395 | -123 | -262 | — | — | — | — | — | |
| Income Taxes | 1 | -29 | 4 | 1 | — | — | — | — | — | |
| Consolidated Net Income | -112 | -366 | -127 | -263 | — | — | — | — | — | |
| Net Income From Continuing Operations | -112 | -366 | -127 | -263 | — | — | — | — | — | |
| Net Income | -112 | -366 | -127 | -263 | — | — | — | — | — | |
| EPS (Recurring) | -1.19 | -3.96 | -1.41 | -3.18 | — | — | — | — | — | |
| EPS (Basic, Before Extraordinaries) | -1.19 | -3.96 | -1.41 | -3.18 | — | — | — | — | — | |
| EPS (Diluted) | -1.19 | -3.96 | -1.41 | -3.18 | — | — | — | — | — | |
| EBITDA | -45 | -331 | -59 | -197 | — | — | — | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | — | — | — | — | — | — | — | — | — | |
| Price To Sales Ratio | 0.71 | 0.69 | 1.49 | 2.11 | — | — | — | — | — | |
| Gross Margin | 68.90 | 69.94 | 69.81 | 68.66 | — | — | — | — | — | |
| Operating Margin | -12.27 | -8.24 | -10.50 | -19.26 | — | — | — | — | — | |
| Net Margin | -13.88 | -44.36 | -15.16 | -34.93 | — | — | — | — | — | |
| Shares Outstanding | 95 | 93 | 91 | 83 | — | — | — | — | — | |
| Market Capitalization | 574 | 572 | 1,248 | 1,589 | — | — | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Kumar Rashmi | Director | Jun 08 '26 | Sale | 4.46 | 15,000 | 66,843 | 171,889 | Jun 09 |
| Bisaro Paul | Director | May 14 '26 | Buy | 3.69 | 7,500 | 27,638 | 97,441 | May 14 |
| Raha Samraat S. | President and CEO | Mar 09 '26 | Buy | 5.00 | 40,000 | 199,844 | 493,104 | Mar 09 |
| Phanstiel S. Louise | Director | Feb 27 '26 | Buy | 4.66 | 48,000 | 223,728 | 281,951 | Feb 27 |
| Phanstiel S. Louise | Director | Feb 26 '26 | Buy | 4.80 | 50,407 | 242,105 | 233,951 | Feb 27 |
| Phanstiel S. Louise | Director | Feb 25 '26 | Buy | 4.74 | 6,100 | 28,890 | 183,544 | Feb 27 |
| DIAZ PAUL J | President and CEO | Oct 11 '24 | Sale | 22.93 | 15,000 | 343,950 | 962,378 | Oct 11 |
| DIAZ PAUL J | President and CEO | Sep 11 '24 | Sale | 26.72 | 15,000 | 400,800 | 977,378 | Sep 12 |
| Muzzey Dale | Chief Scientific Officer | Sep 11 '24 | Sale | 26.17 | 2,100 | 54,961 | 108,013 | Sep 12 |
| Dreismann Heinrich | Director | Sep 09 '24 | Sale | 27.05 | 10,000 | 270,520 | 121,648 | Sep 09 |
| Reitan Colleen F | Director | Sep 03 '24 | Sale | 27.95 | 46,012 | 1,285,851 | 42,533 | Sep 04 |
| Ancona Margaret | SVP, Chief of Staff | Aug 21 '24 | Sale | 27.82 | 11,538 | 320,987 | 79,366 | Aug 23 |
| Kumar Rashmi | Director | Aug 19 '24 | Sale | 28.01 | 7,500 | 210,075 | 77,392 | Aug 20 |
| SPIEGELMAN DANIEL K | Director | Jun 04 '24 | Sale | 22.05 | 3,788 | 83,525 | 32,917 | Jun 04 |
| SPIEGELMAN DANIEL K | Director | Jun 03 '24 | Sale | 22.04 | 3,788 | 83,488 | 36,705 | Jun 04 |